Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 2Head & Neck 2Genitourinary 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Temozolomide 166Magnetic Resonance Spectroscopy 131Radiotherapy 97Specimen Handling 81Radiosurgery 61Cyclophosphamide 56pembrolizumab 52Bevacizumab 52Radiation 48Nivolumab 48Carboplatin 36Biopsy 33Irinotecan 29Etoposide 25Vincristine 24Lomustine 24Topotecan 23Ipilimumab 23Blood Specimen Collection 23Cisplatin 22dinutuximab 21fludarabine 19Surgical Procedures, Operative 19Radiotherapy, Intensity-Modulated 19X-Rays 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
bintrafusp alfa protein, human × CNS × 1 year × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡